The American journal of surgical pathology · 2025
Follicular Helper T-cell Lymphoma With Hodgkin/Reed-Sternberg-Like Cells Versus Classic Hodgkin Lymphoma: A Comparative Study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Petronilho Sara, Poullot Elsa, Andre Axel, Robe Cyrielle, Nouhoum Sako, Fataccioli Virginie, Quintela José Miguel, Claudel Alexis, Brière Josette, Lechapt Emmanuele, Lemonnier François, Henrique Rui, de Leval Laurence, Gaulard Philippe
Аннотация
Lymphomas of T-follicular helper origin (T-follicular helper-cell lymphoma [TFHL]) are often accompanied by an expansion of B-immunoblasts, occasionally with Hodgkin/Reed-Sternberg-like (HRS-like) cells, making the differential diagnosis with classic Hodgkin lymphoma (CHL) difficult. We compared the morphologic, immunophenotypic, and molecular features of 15 TFHL and 12 CHL samples and discussed 4 challenging cases of uncertain diagnosis. Compared with CHL, TFHL disclosed more frequent sparing of subcortical sinuses, high-endothelium venule proliferation, dendritic cell meshwork expansion, T-cell atypia, and aberrant T-cell immunophenotype. HRS-like and HRS cells were CD30+, often CD15+ and EBV infected. There was a variable loss of B-cell markers in both diseases, with an expression of CD20, CD79a, CD19, or OCT-2 more frequently preserved in HRS-like cells of TFHL. The T-cell infiltrate was predominantly CD4+/CD8-, with expression of at least 2 TFH-markers in all TFHL and 75% of CHL. The most useful TFH marker was CD10 (positive in 86% TFHL and no CHL). Twelve/15 TFHL contained CD30+ neoplastic TFH cells, whereas CD30 expression was mostly restricted to HRS cells in CHL. We detected monoclonal TR rearrangements in 75% of TFHL and no CHL; and monoclonal IG rearrangements in 23% of TFHL and 42% of CHL. All TFHL had TET2 mutations; 13/14 presented RHOA mutations, 3 accompanied by DNMT3A and 1 DNMT3A + IDH2 mutations. Three CHL had TET2 mutations, likely attributable to clonal hematopoiesis. Our study further underlines that HRS(-like) cells are not pathognomonic of CHL. Since no single pathologic criterion distinguishes TFHL and CHL, an integrative approach ideally comprising molecular investigations is fundamental.
Предметные рубрики MeSH
HumansHodgkin DiseaseFemaleMiddle AgedBiomarkers, TumorMaleReed-Sternberg CellsAdultAgedImmunophenotypingDiagnosis, DifferentialLymphoma, FollicularT Follicular Helper CellsMutationImmunohistochemistryT-Lymphocytes, Helper-InducerDNA Mutational AnalysisAged, 80 and overDNA Methyltransferase 3ADioxygenasesDNA-Binding Proteins